Attenuation of skeletal muscle atrophy in cancer cachexia by d-myo-inositol 1,2,6-triphosphate

Steve T. Russell, P.M.A. Siren, M.J. Siren, Michael J. Tisdale

Research output: Contribution to journalArticlepeer-review


PURPOSE: To determine the effectiveness of the polyanionic, metal binding agent D-myo-inositol-1,2,6-triphosphate (alpha trinositol, AT), and its hexanoyl ester (HAT), in tissue wasting in cancer cachexia. METHODS: The anti-cachexic effect was evaluated in the MAC16 tumour model. RESULTS: Both AT and HAT attenuated the loss of body weight through an increase in the nonfat carcass mass due to an increase in protein synthesis and a decrease in protein degradation in skeletal muscle. The decrease in protein degradation was associated with a decrease in activity of the ubiquitin-proteasome proteolytic pathway and caspase-3 and -8. Protein synthesis was increased due to attenuation of the elevated autophosphorylation of double-stranded RNA-dependent protein kinase, and of eukaryotic initiation factor 2alpha together with hyperphosphorylation of eIF4E-binding protein 1 and decreased phosphorylation of eukaryotic elongation factor 2. In vitro, AT completely attenuated the protein degradation in murine myotubes induced by both proteolysis-inducing factor and angiotensin II. CONCLUSION: These results show that AT is a novel therapeutic agent with the potential to alleviate muscle wasting in cancer patients.
Original languageEnglish
Pages (from-to)517-527
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Issue number3
Early online date27 Dec 2008
Publication statusPublished - Jul 2009

Bibliographical note

The original publication is available at


  • muscle atrophy
  • alpha trinositol
  • protein kinase R
  • PKR
  • eukaryotic initiation factors
  • eukaryotic elongation factors


Dive into the research topics of 'Attenuation of skeletal muscle atrophy in cancer cachexia by d-myo-inositol 1,2,6-triphosphate'. Together they form a unique fingerprint.

Cite this